Holen Sie sich die Stockscreener-App
89.76
1.27%
1.13
Handel nachbörslich:
89.76
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt GILD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
Layoff Tracker: J&J, Merck Trimming Workforces in China - BioSpace
Sjogren’s Syndrome Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Gilead Sciences, Incyte Corporation, Novartis, GlaxoSmithKline, Janssen Research & Development - Barchart
Gilead Sciences (NASDAQ:GILD) Price Target Raised to $100.00 - MarketBeat
Gilead’s GS-6791 ameliorates arthritis symptoms in mice - BioWorld Online
Intech Investment Management LLC Decreases Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
PNC Financial Services Group Inc. Increases Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Position Increased by Natixis Advisors LLC - MarketBeat
Latham & Watkins Advises on Gilead Sciences' US$3.5 Billion Senior Unsecured Notes Offering - Legal Desire News Network
Watkins Advises on Gilead Sciences' US$3.5 Billion Senior Unsecured Notes Offering - Latham & Watkins LLP
Gilead Sciences (GILD) Announces Issuance of Senior Notes in New Indenture Agreement - GuruFocus.com
Gilead Sciences Issues $3.5 Billion in Senior Notes - Investing.com India
Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch
Gilead Helps Pen a Children’s Book for Families Facing Breast Cancer - CSRwire.com
How Gilead Is Driving Global Health Equity And Innovation - Forbes
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Purchased by First Horizon Advisors Inc. - MarketBeat
Gilead Science to Report Q3 Earnings: What's in the Cards? - MSN
Gilead Sciences, Inc. (NASDAQ:GILD) Stock Holdings Lowered by Ontario Teachers Pension Plan Board - MarketBeat
B. Metzler seel. Sohn & Co. Holding AG Takes $9.52 Million Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Prospera Financial Services Inc Has $6.59 Million Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Gilead discloses GS-441524 prodrugs for treatment of viral infections - BioWorld Online
Ideaya hires Gilead leader to head up commercialization push - FiercePharma
Parnassus Investments LLC Sells 280,937 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Meeder Asset Management Inc. Purchases 42,444 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Belmont Capital LLC Reduces Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences Inc. stock rises Monday, still underperforms market - MarketWatch
Gilead announces impending layoffs, facility closure - LabPulse
26 Analysts Assess Gilead Sciences: What You Need To Know - Benzinga
Royal Bank of Canada Forecasts Strong Price Appreciation for Gilead Sciences (NASDAQ:GILD) Stock - MarketBeat
Amid Seattle downsizing, Gilead cuts 100+ positions at California HQ - FiercePharma
Gilead’s Livdelzi shows promise in PBC clinical trial - Yahoo Finance
Gilead Sciences shares target upgraded, holds rating on HIV event outlook - Investing.com India
5,715 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Bought by Aljian Capital Management LLC - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by TrinityPoint Wealth LLC - MarketBeat
Empowering women, eliminating viral hepatitis: Gilead’s vision to help drive public health solutions - STAT
Gilead’s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis - BioSpace
Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024 - GlobeNewswire Inc.
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Purchased by Swiss National Bank - MarketBeat
Thrivent Financial for Lutherans Boosts Stake in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
14,342 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Bought by Atlanta Consulting Group Advisors LLC - MarketBeat
GILEAD SCIENCES, INC. (GILD) - MSN
How Gilead Sciences' HIV & Other Innovations Are Set to Capture Untapped Markets & Drive Massive Growth!Major Drivers - Smartkarma
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Kentucky Retirement Systems - MarketBeat
CIBC Asset Management Inc Purchases 22,624 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Impax Asset Management Group plc Sells 7,979 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead’s Irish business sees profit slump on falling sales of Covid drug - The Irish Times
Gilead to see Bay Area layoffs in wake of Seattle office closingSan Francisco Business Times - The Business Journals
Gilead Sciences Inc. stock underperforms Friday when compared to competitors - MarketWatch
Form 424B5 GILEAD SCIENCES, INC. - StreetInsider.com
Biotech giant Gilead lays off 104 from Bay Area headquarters, including execs - SFGATE
Cell Therapy Market Poised for Massive Growth (2024-2031) | Gilead Sciences, Inc., Novartis, AG, Vericel Corporation - openPR
Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease - Yahoo Finance
Simplify Asset Management Inc. Buys New Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences (GILD) Reports Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis - StreetInsider.com
Empowered Funds LLC Reduces Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
As an HIV+ activist, I know drug companies aren't doing enough to end AIDS - Yahoo News UK
Dearborn Partners LLC Has $26.76 Million Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Intellectus Partners LLC - MarketBeat
Citigroup Upgrades Gilead Sciences (NASDAQ:GILD) to Strong-Buy - MarketBeat
Gilead and Kite Are Cutting Employees, Closing Seattle, Philadelphia Sites - BioSpace
Gilead Sciences to close Seattle office; shutdown impacts 72 employees - MSN
COVID drugmaker to close Seattle office, lay off 72 workers - The Seattle Times
Gilead Sciences Inc. stock outperforms competitors despite losses on the day - MarketWatch
CAR T-Cell Therapy For Acute Lymphoblastic Leukemia Market on Track for Major Expansion by 2034, According to DelveInsight | Eli Lilly and Company, Gilead Sciences, Novartis, Autolus Therapeutics - Barchart
Gilead, Vertex initiated as new big biotech buys at Citi - Seeking Alpha
Gilead lays off 72 workers in Seattle, plans to shutter R&D support site - Fierce Biotech
ING Groep NV Acquires 109,788 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences to Close Seattle Office, Lay Off 72 Employees Located at Alexandria’s 199 E. Blaine Property - The Registry Seattle
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know - MSN
Brokers Suggest Investing in Gilead (GILD): Read This Before Placing a Bet - Yahoo Finance
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by KBC Group NV - MarketBeat
0.60%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):